<?xml version="1.0" encoding="UTF-8"?>
<p>The DAG questionnaire was adapted to the objectives of the study. Data were collected at the initial visit (in the acute phase), and if possible on day 3, between days 5 and 7, and between days 8 and 10 after the onset of symptoms. The following data were recorded: sociodemographic data, comorbidities and clinical characteristics at baseline (headache, arthralgia, myalgia, fever, rash, fatigue, etc.), impact on quality of life as measured by the EuroQol 5 Dimensions (EQ5D) scale (
 <xref ref-type="supplementary-material" rid="pntd.0007327.s001">S1 Fig</xref>), and treatments used. At the beginning of the epidemic, the medical team of the infectious disease department was trained by a group of rheumatologists, one of whom was a member of the CHIKV patient care team. Patients with CCA were managed in collaboration with the rheumatology department. For patients enrolled from July 2014 onwards (i.e., after adjustment of the protocol for the DAG-2 cohort), an accurate description of affected joints (location, swelling, stiffness, arthritis, enthesitis, joint pain, etc.), and an assessment of peripheral neuropathy with the 
 <italic>douleur neuropathique 4</italic> (DN4, neuropathic pain 4) scale (
 <xref ref-type="supplementary-material" rid="pntd.0007327.s002">S2 Fig</xref>) were also performed.
</p>
